La vendita allo scoperto per Coherus BioSciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Coherus BioSciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Coherus BioSciences (NASDAQ:CHRS) Azioni, Report sulle vendite allo scoperto

Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Coherus BioSciences Inc

COHERUS BIOSCIENCES ORD

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

News

Price Target

Reiteration

Analyst Ratings

CHRS

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

WIIM

Coherus Biosciences shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $4 to $1.5.

UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) from Buy to Neutral and lowers the price target from $4 to $1.5.

Downgrades

UBS Downgrades Coherus BioSciences to Neutral, Lowers Price Target to $1.5

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance

Coherus BioSciences Sees FY24 R&D And SG&A Expenses $250M-$265M

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.29) by 51.72 percent. The company reported quarterly sales of $65.000 million which beat the analyst consensus estimate of $61.366 million by 5.92 percent. This is a 10.70 percent increase over sales of $58.716 million the same period last year.

Earnings

Earnings Beats

Coherus BioSciences Q2 2024 Adj. EPS $(0.14) Beats $(0.29) Estimate, Sales $65.000M Beat $61.366M Estimate

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $9 to $8.

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $8

Coherus BioSciences To Divest YUSIMRY In $40M Upfront All Cash Transaction

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $8 to $7.

Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and raises the price target from $11 to $12.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12

Coherus BioSciences shares are trading lower after the company reported better-than-expected Q1 financial results.

Earnings Misses

Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate

<ul>
<li>New $38.7 million term loan with a May 2029 maturity</li>
<li>$37.5 million royalty monetization financing based on future sales of LOQTORZI&nbsp;and UDENYCA</li>
</ul>

Biotech

Health Care

General

Coherus Announces Full Repayment of Pharmakon Advisors $75M Term Loan

Contracts

Coherus To Collaborate With Cancer Research Institute On Novel Combination Evaluating LOQTORZI With ENB Therapeutics' ENB-003 For Treatment Of Ovarian Cancer

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – Mechanism may enhance antitumor responses with immunotherapy – – First novel immuno-oncology product candidate discovered and developed by Coherus – – The CHS-1000 IND submission is planned for Q2 2024 –
REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.
"Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance. The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response. Reprogramming myeloid cells in the tumor microenvironment holds promise as a new immuno-therapy approach with the aim to overcome resistance to I-O therapy and potentially provide benefit to more cancer patients," said Theresa LaVallee, Ph.D., Chief Development Officer at Coherus. "CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter. We plan to advance CHS-1000 into the clinic both as a single agent and in combination with LOQTORZI&#xAE;."
These data will be presented today in a poster session, and the poster will be available for download at the time of the presentation:
Abstract: 1364/15 Title: <a href="https://www.globenewswire.com/Tracker?data=b-uQ9Bkof9Sji0aB982AtyOYvcv5Xl-9Bg9u2FJd0Z1liW4GB5t0Qgq2Ep1KWsfekasaWY-N33KqwYrlBZtQxusWWKPTiS-GA0mwE7o2RvwYkQg0uXBMa9gl8RdlqFqrV0THxMh1zr2rspAeYvllpvOG6lwLFIVSKQqQWd4DGjecPUH8-DUNb2WvexstyaFmngapN03lg6fyasDGuts65XpKVosuEY8LcQlbErxzHf8tVk_AeFQzQy_1mf9ijcO8Rf11betnAxEADYdPYqkyl5D_0CrjbVV2XycAXZ-ifLk=">Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors</a> Presenting author: Narendiran Rajasekaran, Ph.D. Session PO.IM01.02 – Immune Checkpoints and Inhibitory Molecules 1 Date and Time: Monday, April 8, 2024, 9:00 a.m. – 12:30 p.m. Pacific Daylight Time
Poster data are summarized as follows:
<ul>
<li>CHS-1000 binds specifically and selectively to human ILT4 (LILRB2) with high affinity and showed no cross-reactivity to other LILRB family members.</li>
<li>CHS-1000 efficiently blocks the interaction of ILT4 with its ligands, HLA-A and HLA-G, and reverses ILT4-mediated immunosuppressive functions, leading to activation of M1 macrophages, dendritic cells, and T cells and increases in pro-inflammatory cytokine secretion in in vitro assays.</li>
<li>CHS-1000 is Fc silent and lacks effector function activity in in vitro assays consistent with the engineered modification of the Fc region of the antibody. It also has IgG1‑like PK parameters in human FcRn transgenic mice.
<ul>
<li>ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.</li>
</ul>
</li>
</ul>

Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $13 to $11.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $13 price target.

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target

Coherus BioSciences shares are trading lower after the company reported worse-than-expected Q4 financial results.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Coherus Biosciences (CHRS – Research Report). The...

Truist Financial Remains a Buy on Coherus Biosciences (CHRS)

The 1-Minute Market Report September 22, 2024

Lazard Enhanced Opportunities Portfolio Q2 2024 Commentary

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jasper Therapeutics (JSPR – Research Report) and Coh...

Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)

Warning: CHRS is at high risk of performing badly

The 1-Minute Market Report October 20, 2024

AAPL

ACTV

AFMC

AFSM

ARKK

AVUV

BAPR

BITO

BIZD

BLOK

COPX

CRMT

CRNC

CVLT

DCOM

EMQQ

GOLLQ

ICLN

IDRV

ITOS

IVOO

IVOV

JETS

JSPR

KCCA

KLAC

KRBN

LSCC

MAGS

MAXN

MLKN

MODV

MSFT

MSOS

NVDA

PALL

PAVE

PENG

PGNY

PLAY

POWL

RILY

SIVR

SLVM

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPWRQ

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSLY

SSPY

SVAL

SYLD

TALO

TFIN

TMDV

TNDM

TPHD

TPLC

TPSC

TRUP

TTGT

UAUG

UFPT

UJAN

UMAR

UMAY

UOCT

UPRO

URNM

USMC

USMF

USVM

UTWO

WOLF

Financing

Press Releases

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Management

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Comments

Coherus BioSciences

Vendite allo scoperto

Coherus BioSciences (NASDAQ:CHRS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO